Does this gene-testing biotech company have value as more than a short-squeeze play?
News & Analysis: Bionano Genomics, Inc
The genetic testing specialist is bolstering its leadership ranks.
Analysts expect one of them to skyrocket a lot more than 25%.
This provider of genome mapping tools is showing signs of exponential growth ahead.
The company reported better-than-expected Q1 revenue growth.
The company delivered a pleasant surprise.
BNGO earnings call for the period ending March 31, 2021.
Can you count on this company's novel gene diagnostic technology?
This stock market mover's growth story is just beginning.
No news; just run-of-the-mill volatility.